CLINICAL_TRIALS trial_result · 2026-06-25

Clinical Trial Results: SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity [Phase 2]

Phase 2 trial results for SPI-1005 aimed at prevention and treatment of tobramycin-induced ototoxicity have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Ototoxicity | Phase 2 | Status: COMPLETED | Results posted: 2026-06-25